In Q3 2023, we initiated a global Phase 2 trial of rosnilimab for the treatment of moderate-to-severe rheumatoid arthritis
Top-line data is anticipated mid-year 2025
PD-1+ T cells broadly impact multiple clinically validated drivers of RA pathogenesis
>80% of T cells in RA synovium are PD-1+
- Similar findings are observed in treatment naïve and biologic experienced patients
Adapted from Aletaha and Smolen, JAMA, 2018
Rosnilimab’s potent depletion and agonism reduces T cell proliferation and inflammatory cytokines that cause joint damage
Anti-CD3+ anti-CD28 stimulation of RA patient PBMCs for assessment of depletion and agonism MOA, representative data from N=8 donors Two-way ANOVA, Tukey’s multiple comparison test. ****P<0.0001, ***p <0.001, **p <0.01, *p <0.05. 1. TNFa secretion measured in anti-CD3+ anti-CD28 stimulation of purified DC+T cells from N=4 healthy donors.
To learn more about our clinical trial for Rheumatoid Arthritis please click here.